|
Q2 FY2026
As of Jun 30, 2026
|
Q1 FY2026
As of Mar 31, 2026
|
Q4 FY2025
As of Dec 31, 2025
|
Q3 FY2025
As of Sep 30, 2025
|
Q2 FY2025
As of Jun 30, 2025
|
Q1 FY2025
As of Mar 31, 2025
|
Q4 FY2024
As of Dec 31, 2024
|
Q3 FY2024
As of Sep 30, 2024
|
Q2 FY2024
As of Jun 30, 2024
|
Q1 FY2024
As of Mar 31, 2024
|
Q4 FY2023
As of Dec 31, 2023
|
Q3 FY2023
As of Sep 30, 2023
|
Q2 FY2023
As of Jun 30, 2023
|
Q1 FY2023
As of Mar 31, 2023
|
Q4 FY2022
As of Dec 31, 2022
|
Q3 FY2022
As of Sep 30, 2022
|
Q2 FY2022
As of Jun 30, 2022
|
Q1 FY2022
As of Mar 31, 2022
|
Q4 FY2021
As of Dec 31, 2021
|
Q3 FY2021
As of Sep 30, 2021
|
|
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Assets | ||||||||||||||||||||
| Debt securities, available for sale, at fair value, net of allowance for credit losses of $0.0 (2025 - $0.0) (cost - $5,180.5; 2025 - $5,118.3) | ||||||||||||||||||||
| Debt securities, trading, at fair value (cost - $88.6; 2025 - $114.6) | ||||||||||||||||||||
| Short-term investments, at fair value (cost - $7.2; 2025 - $28.4) | ||||||||||||||||||||
| Investments in related party investment funds, at fair value | ||||||||||||||||||||
| Other long-term investments, at fair value (cost - $399.3; 2025 - $421.9) (includes related party investments at fair value of $224.5 (2025 - $216.1)) | ||||||||||||||||||||
| Equity securities, at fair value (cost - $0.0; 2023 - $1.9) | ||||||||||||||||||||
| Total investments | ||||||||||||||||||||
| Cash and cash equivalents | ||||||||||||||||||||
| Restricted cash and cash equivalents | ||||||||||||||||||||
| Redemption receivable from related party investment fund | ||||||||||||||||||||
| Due from brokers | ||||||||||||||||||||
| Interest and dividends receivable | ||||||||||||||||||||
| Insurance and reinsurance balances receivable, net | ||||||||||||||||||||
| Deferred acquisition costs, net | ||||||||||||||||||||
| Unearned premiums ceded | ||||||||||||||||||||
| Loss and loss adjustment expenses recoverable, net | ||||||||||||||||||||
| Deferred tax asset | ||||||||||||||||||||
| Goodwill | ||||||||||||||||||||
| Intangible assets | ||||||||||||||||||||
| Other assets | ||||||||||||||||||||
| Assets held for sale | ||||||||||||||||||||
| Total assets | ||||||||||||||||||||
| Liabilities | ||||||||||||||||||||
| Loss and loss adjustment expense reserves | ||||||||||||||||||||
| Unearned premium reserves | ||||||||||||||||||||
| Reinsurance balances payable | ||||||||||||||||||||
| Deposit liabilities | ||||||||||||||||||||
| Deferred gain on retroactive reinsurance | ||||||||||||||||||||
| Debt | ||||||||||||||||||||
| Total securities sold, not yet purchased | ||||||||||||||||||||
| Securities sold under an agreement to repurchase | ||||||||||||||||||||
| Due to brokers | ||||||||||||||||||||
| Deferred tax liability | ||||||||||||||||||||
| Liability-classified capital instruments | ||||||||||||||||||||
| Share repurchase liability | ||||||||||||||||||||
| Accounts payable, accrued expenses and other liabilities | ||||||||||||||||||||
| Other liabilities | ||||||||||||||||||||
| Liabilities held for sale | ||||||||||||||||||||
| Total liabilities | ||||||||||||||||||||
| Shareholders’ equity | ||||||||||||||||||||
| Series B preference shares (2025 - par value $0.10; authorized and issued: 8,000,000) | ||||||||||||||||||||
| Common shares (issued and outstanding: 116,065,965 (2025 - 116,989,799) | ||||||||||||||||||||
| Additional paid-in capital | ||||||||||||||||||||
| Retained earnings | ||||||||||||||||||||
| Accumulated other comprehensive income (loss), net of tax | ||||||||||||||||||||
| Shareholders’ equity attributable to SiriusPoint shareholders | ||||||||||||||||||||
| Noncontrolling interests | ||||||||||||||||||||
| Total shareholders’ equity | ||||||||||||||||||||
| Total liabilities, noncontrolling interests and shareholders’ equity |
Loading...
